Division of Biology and Chemistry (BIO)
The Division of Biology and Chemistry at PSI is subdivided into three laboratories pursuing research in the areas of structural biology, bioimaging and radiopharmacy.
News
Bringing information into the cell
Researchers at the Paul Scherrer Institute PSI have elucidated an important part of a siganalling pathway that transmits information through the cell membrane into the interior of a cell. This exists in all mammals and plays an important role, among other things, in the regulation of the heartbeat. The new findings could lead to new therapies.
A biotechnological revolution
Gebhard Schertler is head of the research division Biology and Chemistry at the Paul Scherrer Institute PSI and professor for Structural Biology at ETH Zurich. In this interview he talks about biological research at PSI and the future of drug development.
Biological light sensor filmed in action
Using X-ray laser technology, a team led by researchers of the Paul Scherrer Institute PSI has recorded one of the fastest processes in biology. In doing so, they produced a molecular movie that reveals how the light sensor retinal is activated in a protein molecule. Such reactions occur in numerous organisms. The movie shows for the first time how a protein efficiently controls the reaction of the embedded light sensor.
Cristina Müller (CRS) receives the Marie Curie Award
The Marie Curie Award, the most prestigious price by the European Association of Nuclear Medicine, has been awarded in 2018 for the project "Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer", lead by Christina Müller in collaboration with Nick van der Meulen (LRC/NES) EANM-Website(link is external).
Araris Biotech among top 5 in business plan ranking at >>venture2018>>
Araris Biotech, a Spin-Off company in foundation from the Center for Radiopharmaceutical Sciences (Prof. Roger Schibli) at the BIO division, has been ranked in the TOP5 in the business plan competition of >>Venture>>(link is external). Araris is focusing on the development of a new method for the generation of antibody-drug conjugates (ADCs) with a well-defined, optimal antibody-to-drug ratio. The technology will be used to establish a drug development platform for targeted therapies and diagnostic applications. more info(link is external)
Petersen Investigator award in 2018 goes to the Center for Radiopharmaceutical Sciences at PSI
The Neuroendocrine Tumor Research Foundation (NETRF) is committed to funding the most promising research in order to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers. In January 2018 the Board of Directors has awarded a Petersen Investigator award to the team of Professor Roger Schibli for their research proposal titled, “Simultaneous Auger-Electron and β--Particle Therapy of Metastasized NET Using 161Tb-DOTATOC”. more info(link is external)
